Prostate cancer hijacks tumor cell biorhythm to evade hormone therapy

Netherlands Cancer Institute

Hormone therapy is successful at keeping metastatic prostate cancer under control, but eventually the tumor cells become resistant to it. An unexpected potential solution has now emerged in medicines not designed to fight cancer, but to target proteins that regulate a cell’s circadian rhythm.

An international team of researchers led by the Netherlands Cancer Institute will publish this discovery June 27, 2022, in the renowned journal Cancer Discovery, a journal of the American Association for Cancer Research. (This link will work as soon as the article is posted).


Prostate cancer is a tumor type that develops under the influence of hormones, primarily testosterone. Patients with metastatic prostate cancer often receive treatment with anti-hormonal therapy, which inhibits the signal sent out by testosterone that stimulates tumor growth.

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.